Posted on October 21, 2025 SOM Biotech secures clear registrational path for SOM3355 in Huntington’s disease after FDA End-of-Phase 2 Meeting
Posted on October 7, 2025 SOM Biotech will attend the Huntington Study Group Annual Event in Nashville, Oct 10-13, 2025
Posted on September 15, 2025 SOM Biotech receives positive EMA COMP opinion on European Orphan Drug Designation for SOM3355 for treatment of Huntington’s Disease
Posted on July 30, 2025 SOM is pleased to announce that End-of-Phase2 meeting with FDA is set mid-September
Posted on July 10, 2025 Extremely positive findings from the PK/PD study included in the Phase2b reassuring SOM3355 cardiovascular safety beyond expectations.
Posted on February 17, 2025 SOM Biotech will attend Bio-Neuroscience Conference from February 25th to February 27th 2025
